Impilo is a Nordic investment company focused solely on investments in companies operating in the pharmaceutical, medical technology, healthcare services and other health-related industries. Our starting point is that our portfolio companies must contribute to a positive and sustainable development of the communities and markets in which they operate in order to remain successful in the long term. This is a conviction that is embedded in our investment strategy since it necessitates a deeper understanding and reduces risks. This way, Impilo invests in people’s opportunities to enjoy healthier lives in the future.
Location: Sweden, Stockholm
Employees: 11-50
Founded date: 2017
Investment Type: Venture Capital
Portfolio 10
| Date | Name | Website | Total Raised | Location |
| 26.01.2021 | Scantox | scantox.com | - | Denmark, R... |
| 20.01.2021 | Mallax Pha... | mallaxpharma.com | - | Sweden, St... |
| - | Humana AB | humana.se | - | Sweden, St... |
| - | NutraQ | nutraq.com | - | Norway, Os... |
| - | Immedica P... | immedica.com | - | - |
| - | Euro Accid... | euroaccident.se | - | Sweden, St... |
| - | Ferrosan M... | ferrosanmedicaldevices.com | - | Denmark, C... |
| - | Cavidi | cavidi.se | $11.5M | Sweden, Up... |
| - | Apotek Hjä... | apotekhjartat.se | - | Sweden, So... |
| - | The Fertil... | thefertilitypartnership.com | - | United Kin... |
News 18
| Date | Title | Description |
| 16.09.2021 | Impilo has closed its second investment pool | Impilo AB, the Nordic investment company focused on healthcare investments, has secured new commitments from new and existing investors of SEK 6bn (EUR 590m) and significantly exceeding its target amount. The capital raised enables new plat... |
| 01.07.2021 | Mallax acquires Sana Pharma Medical and creates a new Nordic pharmaceutical platform | Mallax Pharmaceuticals AB (”Mallax”) has acquired Sana Pharma Medical AS (”SPM” or the “Company”) and creates a new Nordic pharmaceutical platform. |
| 23.06.2021 | Impilo’s divestment of NutraQ to Orkla completed | On 15 June 2021, the sale of NutraQ to Orkla Health was completed after approval from all relevant competition authorities. NutraQ is a leading supplier of subscription-based health and wellness products in the Nordic region. The company wa... |
| 22.03.2021 | Aeglea BioTherapeutics and Immedica Announce Commercialization Agreement for Pegzilarginase for the Treatment of Arginase 1 Deficiency in Europe and Middle East | Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, and Immedica Pharma AB (Immedica) today announc... |
| 20.01.2021 | Impilo Acquires Scantox A/S, a Leading Danish Pre-Clinical Contract Research Organization | Today, the Danish pre-clinical contract research organization (“CRO”), Scantox A/S (“Scantox” or the “Company”) announced that it has been acquired by the leading Nordic healthcare investment company, Impilo, together with the management te... |
| 04.01.2021 | Immedica and WinHealth enter agreement giving Winhealth rights to Ravicti® in China and several other Asia-Pacific countries | Immedica Pharma AB and Hongkong WinHealth Pharma Group CO., Ltd, today announce that they have entered an agreement under which WinHealth gains the exclusive commercial rights to Ravicti® (glycerol phenylbutyrate), in a territory covering t... |
| 15.12.2020 | Impilo and Anders Larnholt form a partnership to create a new pan‐European pharmaceutical platform | Impilo is pleased to have partnered with Anders Larnholt, an experienced pharma and healthcare executive, to create a new platform; Mallax Pharmaceuticals AB (“Mallax”). Mallax was founded in Sweden, with the aim of building a company with ... |
| 06.11.2020 | Immedica acquires the rights for Ravicti® and Buphenyl® for Japan from Horizon Therapeutics plc. | Immedica today announces that it has acquired the rights for the products Buphenyl® (sodium phenylbutyrate) and Ravicti® (glycerol phenylbutyrate) indicated for the treatment of Urea Cycle Disorders (UCD), in Japan from Horizon Therapeutics... |
| 29.04.2020 | PharmaMar signs an agreement with Immedica | PharmaMar signs an agreement with Immedica Pharma to market lurbinectedin in Eastern Europe, the UK, Ireland, the Nordic countries and some Middle Eastern countries |
| 19.11.2019 | The Swedish Financial Supervisory Authority has approved the consortium of investors arranged by Impilo as new owners of Euro Accident Livförsäkring | - |
Show more
Mentions in press and media 12
| Date | Title | Description |
| 25.10.2024 | Data from the phase 3 SIERRA trial of Iomab-B presented at the annual European Association of Nuclear Medicine (EANM) Congress 2024 | Data from the phase 3 SIERRA trial of Iomab-B presented at the annual European Association of Nuclear Medicine (EANM) Congress 2024 Fri, Oct 25, 2024 11:30 CET Report this content Stockholm, October 25, 2024 – Immedica is pleased to announc... |
| 20.09.2024 | Joint acquisition of Immedica Pharma completed | Joint acquisition of Immedica Pharma completed Fri, Sep 20, 2024 08:00 CET Report this content Stockholm, September 20, 2024 – KKR, a leading global investment firm, and Impilo, a Nordic healthcare investment firm, have today announced the ... |
| 23.04.2024 | Leading global investment firm KKR and Nordic healthcare investment firm Impilo enters strategic partnership together with Immedica management | Leading global investment firm KKR and Nordic healthcare investment firm Impilo enters strategic partnership together with Immedica management Tue, Apr 23, 2024 07:15 CET Report this content Stockholm, April 23, 2024 –Investment funds manag... |
| 02.02.2024 | The Nomination Committee's proposal regarding the Board of Directors of Humana for the 2024 AGM | The Nomination Committee's proposal regarding the Board of Directors of Humana for the 2024 AGM Fri, Feb 02, 2024 15:44 CET Report this content Ahead of the Annual General Meeting 2024, The Nomination Committee proposes that the Board of Di... |
| 02.02.2024 | Impilo invests in Avia Pharma – a leading OTC and Rx pharmaceutical platform | Impilo invests in Avia Pharma – a leading OTC and Rx pharmaceutical platform Fri, Feb 02, 2024 15:00 CET Report this content STOCKHOLM, Sweden, 2 February 2024 – Impilo has closed its investment in Avia Pharma Holding AB (“Avia” or the “Com... |
| 16.08.2023 | Impilo invests in Pelago Bioscience – a fast-growing drug discovery research partner | Impilo invests in Pelago Bioscience – a fast-growing drug discovery research partner Wed, Aug 16, 2023 12:00 CET Report this content STOCKHOLM, Sweden, 16 August 2023 – Impilo invests in Pelago Bioscience AB (“Pelago” or the “Company”) and ... |
| 16.08.2023 | Impilo acquires VaccinDirekt – the leading Nordic retail vaccination provider | Impilo acquires VaccinDirekt – the leading Nordic retail vaccination provider Wed, Aug 16, 2023 12:00 CET Report this content STOCKHOLM, Sweden, 16 August 2023 – Impilo has acquired VaccinDirekt from SEB Private Equity and partners with the... |
| 29.06.2023 | Impilo invests in Decon – a leading mobility player | Impilo invests in Decon – a leading mobility player Thu, Jun 29, 2023 13:16 CET Report this content June 29, 2023 – Impilo has acquired a majority position in Decon Wheel AB (“Decon”), a developer and producer of high-quality power assist e... |
| 06.02.2023 | The Nomination Committee's proposal regarding the Board of Humana for the 2023 AGM | The Nomination Committee's proposal regarding the Board of Humana for the 2023 AGM Mon, Feb 06, 2023 09:28 CET Report this content Ahead of the Annual General Meeting 2023, The Nomination Committee proposes that the Board of Directors, for ... |
| 12.04.2022 | Impilo presents its Sustainability Report for 2021 | Impilo presents its Sustainability Report for 2021 Tue, Apr 12, 2022 10:36 CET Report this content During 2021, we have taken important steps to create more value from our sustainability efforts by better articulating the health impact of o... |
Show more